The combination of antagonism at histamine H 3 receptor and the stimulation of insulin secretion have been proposed as an approach to new dual therapeutic agents for the treatment of type 2 diabetes mellitus associated with obesity. We have designed and synthesized a new series of non-imidazole derivatives, based on a basic amine ring connected through an alkyl spacer of variable length to a phenoxysulfonylurea moiety. These compounds were initially evaluated for histamine H 3 receptor binding affinities, suggesting that a propoxy chain linker between the amine and the core ring could be essential for optimal binding affinity. Compound 56, 1-(naphthalen-1-yl)-3-[(p-(3-pyrrolidin-1-ylpropoxy)benzene)]sulfonylurea exhibited the best H 3 antagonism affinity. However, since all these derivatives failed to block K ATP channels, the link of these two related moieties should not be considered a good pharmacophore for obtaining new dual H 3 antagonists with insulinotropic activity, suggesting the necessity to propose a new chemical hybrid prototype.
Introduction
Obesity is one of today's major health problems, affecting 400 million people throughout the world. Its alarming rising prevalence and the health risks associated with this disease warrant obesity as one of the most challenging therapeutic areas in the 21 st century. Closely linked to obesity is the wide spread increase of type 2 diabetes [1] , emerging as a new epidemic: diabesity. [2] The lack of efficacious drugs for this new disease makes this field one of the most attractive targets.
The histamine H 3 receptor has been known to play a critical role in homeostasis regulatory functions, such as control of food intake and maintenance of body weight. [3] The histamine H 3 receptor is an important G protein-coupled receptor, identified in 1983 by Arrang et. al [4] and cloned and characterized in 1999. [5] The histamine H 3 receptor has been described as a presynaptic autoreceptor [6] [7] [8] mainly expressed in the central nervous system (CNS), regulating histamine biosynthesis and release, as well as a heteroreceptor on non-histaminergic neurons, where it is capable of inhibiting the release of other important neurotransmitters, such as acetylcholine, noradrenaline, dopamine and serotonin. [9] [10] [11] [12] The blockade of this negative feedback mechanism with histamine H 3 receptor antagonists/inverse agonists suggests that they would be useful for the treatment of a variety of CNS disorders affecting cognition, sleep and energy homeostasis.
[13]
Many classes of potent H 3 receptor antagonists have been reported in the reference literature. Imidazolebased compounds such as ciproxifan, clobenpropit, thioperamide and SCH79687 [14] [15] [16] [17] were the first published H 3 receptor antagonists/inverse agonists derived from the endogenous neurotransmitter histamine and containing the classical structure in the form of an imidazole ring connected by a spacer to a polar group, which is attached to a lipophilic end group. [18] The potential liability of imidazole-containing compounds with respect to cytochrome P450 inhibition and drug-drug interactions led to the development of potent and selective non-imidazole derivatives, including compounds such as ABT-239 1, UCL 1972 2, JNJ-5207852 3, GSK-189254 4, Novo Nordisk's 5 and Merck's 6 ( Figure 1 ). [19] [20] [21] [22] [23] These intense efforts made by numerous pharmaceutical companies led to the development of a new refined H 3 antagonist pharmacophore model which contains three parts: a basic amine moiety (western part) able to interact with ASP3.32, an amino acid of the receptor [24] , linked via a variable alkyl spacer to a central core, and an additional eastern part displaying a high chemical diversity ( (Fig. 3 ). These compounds are antagonists of the -cell ATP-dependent K + channel (KATP) and they promote insulin secretion. All of them share a phenylsulfonylurea group with para-substitution on the phenyl ring in their structure. Therefore, this sulfonylurea moiety was incorporated into our molecules with the goal of providing antagonism of K ATP channels and anti-diabetic activity. These observations suggested to us that the combination of H 3 receptor antagonism and the stimulation of insulin secretion might result in synergistic improvements in type 2 diabetes associated with obesity. In this report, we describe our initial hit-finding proposal towards new pharmacodynamic hybrids with dual mechanisms of action. Our strategy towards these dual acting compounds was the multiple target approach designing one new drug by combining two related pharmacophore elements in one structure (Fig. 4) . This approach has been carried out by linking the known H 3 R antagonist template to a phenylsulfonylurea moiety (sulfonylurea drug structure related to the insulinotropic effect).
Based on this strategy and as part of our ongoing program to develop new anti-obesity drugs, we report the synthesis, human H 3 and K ATP channel binding affinities and preliminary SAR of several members of this novel series of non-imidazole derivatives. Historically, many of the reported H 3 antagonists have shown substantial hERG-channel inhibition which represents a potential safety liability. [31] [32] Drugs that block hERG have been associated with QT interval prolongation as well as serious, and sometimes fatal, cardiac arrhythmias (including torsade de pointes). [33] Blockade of the hERG channel poses a risk of cardiac toxicity and has become a critical issue for regulatory agencies and the pharmaceutical industry. [34] This problem has recently been addressed. [35] In an attempt to overcome hERG-channel inhibition related to H 3 antagonists, we decided to evaluate all of the synthesized compounds for the hERG ion channel inhibitory affinity.
Chemistry
Forty-four sulfonylurea and ten sulfonamide derivatives were synthesized using the four-step protocol outlined in Scheme 1. Dropwise addition of chlorosulfonic acid to an ice-cooled solution of the corresponding bromoalkoxyphenyl derivatives (1-3) dissolved in dichloromethane (DCM) gave chlorosulfonyl compounds 4-6, substituted only at the para position due to steric impediments ortho to the alkoxy group.
Conversion of derivatives 4-6 to the corresponding sulfonamides (7-9) was accomplished via treatment isocyanate, reflux, 4h, 71% in two steps.
Results and discussion
The first objective of this preliminary study was to evaluate the synthesized compounds as H 3 receptor
antagonists. Initially, we synthesized a series of sulfonylurea derivatives with five different substituents in the eastern part of the molecules in order to evaluate the influence of the substituent on the urea rest. The substituents were both aliphatic (isopropyl and cyclohexyl), and aromatic (phenyl, 2,5-dichlorophenyl and 4-trifluoromethylphenyl). At the same time, a series of sulfonamide derivatives was obtained as the precursors of the sulfonylurea compounds. The in vitro H 3 receptor binding data for these compounds is summarized in Tables 1 and 2 Comparing the different electronic effects caused by the substituents on the phenyl rest, no substantial differences were observed. Steric effect seems to be more important for these compounds.
Compound 56, substituted with a 1-naphthyl group, was the most potent sulfonylurea for the H 3 receptor
with an IC 50 = 0.08 µM.
In addition, we examined the effects of these synthesized compounds on the ATP-sensitive K + -channel (K ATP ) channel. Unfortunately, no K ATP channel blocker activity was observed. Therefore, these compounds are unlikely to play a role in the stimulation of insulin secretion from pancreatic -cells and consequently, we are not able to assert that they could exert insulinotropic activity. 
Experimental protocols

General methods
All reagents and solvents were purchased from commercial sources. E. Merck (Darmstadt, Germany), 
General procedure for the preparation of 4-(bromoalkoxy)benzenesulfonyl chloride derivatives (4-6)
Chlorosulfonic acid (20.00 mmol) was added dropwise to an ice-salt bath solution of the appropriate bromoalkoxyphenyl (1-3) (10.00 mmol) dissolved in dichloromethane (25 mL) at -10ºC. After stirring for 2 hours, the reaction mixture was allowed to warm to room temperature, and was stirred for an additional hour.
The reaction mixture was then poured into 200 g of cracked ice and extracted with dichloromethane. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The solvent was removed under reduced pressure to afford the corresponding 4-(bromoalkoxy)benzenesulfonyl chloride derivatives (4-6).
4-(2-bromoethoxy)benzenesulfonyl chloride (4)
White solid. 
4-(3-bromopropoxy)benzenesulfonyl chloride (5)
Rose solid. 
4-(4-bromobutoxy)benzenesulfonyl chloride (6)
Beige oil. Yield: 56%. IR (NaCl, cm 
General procedure for the preparation of 4-(bromoalkoxy)benzenesulfonamide derivatives (7-9)
The corresponding 4-(bromoalkoxy)benzenesulfonyl chloride (4-6) (30.00 mmol) was dissolved in 80 mL of dichloromethane and cooled to 0ºC. Next, the reaction mixture was stirred under ammonia gas atmosphere for 45 minutes. The obtained precipitate was filtered off and the solvent was removed under vacuum to yield 4-(bromoalkoxy)benzenesulfonamide derivatives (7-9).
4-(2-bromoethoxy)benzenesulfonamide (7)
4-(3-bromopropoxy)benzenesulfonamide (8)
4-(4-bromobutoxy)benzenesulfonamide (9)
Beige oil. 
4-[(2-(pyrrolidin-1-yl)ethoxy)]benzenesulfonamide (10)
4-[(2-(piperidin-1-yl)ethoxy)]benzenesulfonamide (11)
4-{2-[(4-ethoxycarbonyl)piperidin-1-yl]ethoxy}benzenesulfonamide (12)
4-[(3-(pyrrolidin-1-yl)propoxy)]benzenesulfonamide (13)
4-[(3-(piperidin-1-yl)propoxy)]benzenesulfonamide (14)
Beige solid. 
4-[(4-(piperidin-1-yl)butoxy)]benzenesulfonamide (18)
General procedure for the preparation of 4-(aminealkoxy)benzenesulfonylurea derivatives (20-64)
A solution of 10% of NaOH (5.00 mmol) was added to a solution of the corresponding 4-(aminealkoxy)benzenesulfonamide 10-19 (5.00 mmol) in acetone (25 mL). After 10 minutes of stirring, the solvent was removed under reduced pressure. The solid was redissolved in acetone (30 mL) and the reaction mixture was stirred under reflux. The appropriate isocyanate derivative (10.00 mmol) was added dropwise and the mixture was stirred at reflux for 4 hours. The solvent was concentrated to dryness in vacuo and the obtained residue was purified by flash column chromatography (CH 2 Cl 2 /MeOH 95:5) in order to afford 20-64 derivatives.
1-isopropyl-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea (20)
1-phenyl-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea (21)
1-cyclohexyl-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea (22)
1-(2,5-dichlorophenyl)-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea (23)
1-(4-trifluoromethylphenyl)-3-[4-(2-pyrrolidin-1-ylethoxy)benzene]sulfonylurea (24)
1-phenyl-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea (26)
1-cyclohexyl-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea (27)
1-(2,5-dichlorophenyl)-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea (28)
1-(4-trifluoromethylphenyl)-3-[4-(2-piperidin-1-ylethoxy)benzene]sulfonylurea (29)
1-isopropyl-3-[4-(3-pyrrolidin-1-ylpropoxy)benzene]sulfonylurea (31)
White
1-cyclohexyl-3-[4-(3-pyrrolidin-1-ylpropoxy)benzene]sulfonylurea (33)
1-(2,5-dichlorophenyl)-3-[4-(3-pyrrolidin-1-ylpropoxy)benzene]sulfonylurea (34)
White solid. Yield: 2%. M.p: 166-167ºC. IR (KBr, cm -1 ): 3426 (m, ν N-H ); 1626 (s, ν C=O ); 1252 (vs, ν C-O
